Literature DB >> 34464958

Lectins enhance SARS-CoV-2 infection and influence neutralizing antibodies.

Amalio Telenti1, Davide Corti2, Florian A Lempp3, Leah B Soriaga3, Martin Montiel-Ruiz3, Fabio Benigni4, Julia Noack3, Young-Jun Park5, Siro Bianchi4, Alexandra C Walls5, John E Bowen5, Jiayi Zhou3, Hannah Kaiser3, Anshu Joshi5, Maria Agostini3, Marcel Meury3, Exequiel Dellota3, Stefano Jaconi4, Elisabetta Cameroni4, Javier Martinez-Picado6,7,8, Júlia Vergara-Alert9, Nuria Izquierdo-Useros6,10, Herbert W Virgin3,11,12, Antonio Lanzavecchia4, David Veesler5, Lisa A Purcell13.   

Abstract

SARS-CoV-2 infection-which involves both cell attachment and membrane fusion-relies on the angiotensin-converting enzyme 2 (ACE2) receptor, which is paradoxically found at low levels in the respiratory tract1-3, suggesting that there may be additional mechanisms facilitating infection. Here we show that C-type lectin receptors, DC-SIGN, L-SIGN and the sialic acid-binding immunoglobulin-like lectin 1 (SIGLEC1) function as attachment receptors by enhancing ACE2-mediated infection and modulating the neutralizing activity of different classes of spike-specific antibodies. Antibodies to the amino-terminal domain or to the conserved site at the base of the receptor-binding domain, while poorly neutralizing infection of ACE2-overexpressing cells, effectively block lectin-facilitated infection. Conversely, antibodies to the receptor binding motif, while potently neutralizing infection of ACE2-overexpressing cells, poorly neutralize infection of cells expressing DC-SIGN or L-SIGN and trigger fusogenic rearrangement of the spike, promoting cell-to-cell fusion. Collectively, these findings identify a lectin-dependent pathway that enhances ACE2-dependent infection by SARS-CoV-2 and reveal distinct mechanisms of neutralization by different classes of spike-specific antibodies.
© 2021. The Author(s), under exclusive licence to Springer Nature Limited.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 34464958     DOI: 10.1038/s41586-021-03925-1

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  57 in total

1.  The protein expression profile of ACE2 in human tissues.

Authors:  Feria Hikmet; Loren Méar; Åsa Edvinsson; Patrick Micke; Mathias Uhlén; Cecilia Lindskog
Journal:  Mol Syst Biol       Date:  2020-07       Impact factor: 11.429

2.  CD147-spike protein is a novel route for SARS-CoV-2 infection to host cells.

Authors:  Ke Wang; Wei Chen; Zheng Zhang; Yongqiang Deng; Jian-Qi Lian; Peng Du; Ding Wei; Yang Zhang; Xiu-Xuan Sun; Li Gong; Xu Yang; Lei He; Lei Zhang; Zhiwei Yang; Jie-Jie Geng; Ruo Chen; Hai Zhang; Bin Wang; Yu-Meng Zhu; Gang Nan; Jian-Li Jiang; Ling Li; Jiao Wu; Peng Lin; Wan Huang; Liangzhi Xie; Zhao-Hui Zheng; Kui Zhang; Jin-Lin Miao; Hong-Yong Cui; Min Huang; Jun Zhang; Ling Fu; Xiang-Min Yang; Zhongpeng Zhao; Shihui Sun; Hongjing Gu; Zhe Wang; Chun-Fu Wang; Yacheng Lu; Ying-Ying Liu; Qing-Yi Wang; Huijie Bian; Ping Zhu; Zhi-Nan Chen
Journal:  Signal Transduct Target Ther       Date:  2020-12-04

3.  REGN-COV2, a Neutralizing Antibody Cocktail, in Outpatients with Covid-19.

Authors:  David M Weinreich; Sumathi Sivapalasingam; Thomas Norton; Shazia Ali; Haitao Gao; Rafia Bhore; Bret J Musser; Yuhwen Soo; Diana Rofail; Joseph Im; Christina Perry; Cynthia Pan; Romana Hosain; Adnan Mahmood; John D Davis; Kenneth C Turner; Andrea T Hooper; Jennifer D Hamilton; Alina Baum; Christos A Kyratsous; Yunji Kim; Amanda Cook; Wendy Kampman; Anita Kohli; Yessica Sachdeva; Ximena Graber; Bari Kowal; Thomas DiCioccio; Neil Stahl; Leah Lipsich; Ned Braunstein; Gary Herman; George D Yancopoulos
Journal:  N Engl J Med       Date:  2020-12-17       Impact factor: 91.245

4.  Comprehensive mapping of mutations in the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human plasma antibodies.

Authors:  Allison J Greaney; Andrea N Loes; Katharine H D Crawford; Tyler N Starr; Keara D Malone; Helen Y Chu; Jesse D Bloom
Journal:  Cell Host Microbe       Date:  2021-02-08       Impact factor: 21.023

5.  Mapping Neutralizing and Immunodominant Sites on the SARS-CoV-2 Spike Receptor-Binding Domain by Structure-Guided High-Resolution Serology.

Authors:  Luca Piccoli; Young-Jun Park; M Alejandra Tortorici; Nadine Czudnochowski; Alexandra C Walls; Martina Beltramello; Chiara Silacci-Fregni; Dora Pinto; Laura E Rosen; John E Bowen; Oliver J Acton; Stefano Jaconi; Barbara Guarino; Andrea Minola; Fabrizia Zatta; Nicole Sprugasci; Jessica Bassi; Alessia Peter; Anna De Marco; Jay C Nix; Federico Mele; Sandra Jovic; Blanca Fernandez Rodriguez; Sneha V Gupta; Feng Jin; Giovanni Piumatti; Giorgia Lo Presti; Alessandra Franzetti Pellanda; Maira Biggiogero; Maciej Tarkowski; Matteo S Pizzuto; Elisabetta Cameroni; Colin Havenar-Daughton; Megan Smithey; David Hong; Valentino Lepori; Emiliano Albanese; Alessandro Ceschi; Enos Bernasconi; Luigia Elzi; Paolo Ferrari; Christian Garzoni; Agostino Riva; Gyorgy Snell; Federica Sallusto; Katja Fink; Herbert W Virgin; Antonio Lanzavecchia; Davide Corti; David Veesler
Journal:  Cell       Date:  2020-09-16       Impact factor: 41.582

6.  Studies in humanized mice and convalescent humans yield a SARS-CoV-2 antibody cocktail.

Authors:  Johanna Hansen; Alina Baum; Kristen E Pascal; Vincenzo Russo; Stephanie Giordano; Elzbieta Wloga; Benjamin O Fulton; Ying Yan; Katrina Koon; Krunal Patel; Kyung Min Chung; Aynur Hermann; Erica Ullman; Jonathan Cruz; Ashique Rafique; Tammy Huang; Jeanette Fairhurst; Christen Libertiny; Marine Malbec; Wen-Yi Lee; Richard Welsh; Glen Farr; Seth Pennington; Dipali Deshpande; Jemmie Cheng; Anke Watty; Pascal Bouffard; Robert Babb; Natasha Levenkova; Calvin Chen; Bojie Zhang; Annabel Romero Hernandez; Kei Saotome; Yi Zhou; Matthew Franklin; Sumathi Sivapalasingam; David Chien Lye; Stuart Weston; James Logue; Robert Haupt; Matthew Frieman; Gang Chen; William Olson; Andrew J Murphy; Neil Stahl; George D Yancopoulos; Christos A Kyratsous
Journal:  Science       Date:  2020-06-15       Impact factor: 47.728

7.  Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection.

Authors:  Xin Zou; Ke Chen; Jiawei Zou; Peiyi Han; Jie Hao; Zeguang Han
Journal:  Front Med       Date:  2020-03-12       Impact factor: 4.592

8.  SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19.

Authors:  Peter Chen; Ajay Nirula; Barry Heller; Robert L Gottlieb; Joseph Boscia; Jason Morris; Gregory Huhn; Jose Cardona; Bharat Mocherla; Valentina Stosor; Imad Shawa; Andrew C Adams; Jacob Van Naarden; Kenneth L Custer; Lei Shen; Michael Durante; Gerard Oakley; Andrew E Schade; Janelle Sabo; Dipak R Patel; Paul Klekotka; Daniel M Skovronsky
Journal:  N Engl J Med       Date:  2020-10-28       Impact factor: 91.245

Review 9.  Immunopathology of Hyperinflammation in COVID-19.

Authors:  Joshua N Gustine; Dennis Jones
Journal:  Am J Pathol       Date:  2020-09-11       Impact factor: 4.307

10.  Ultrapotent human antibodies protect against SARS-CoV-2 challenge via multiple mechanisms.

Authors:  M Alejandra Tortorici; Martina Beltramello; Florian A Lempp; Dora Pinto; Ha V Dang; Laura E Rosen; Matthew McCallum; John Bowen; Andrea Minola; Stefano Jaconi; Fabrizia Zatta; Anna De Marco; Barbara Guarino; Siro Bianchi; Elvin J Lauron; Heather Tucker; Jiayi Zhou; Alessia Peter; Colin Havenar-Daughton; Jason A Wojcechowskyj; James Brett Case; Rita E Chen; Hannah Kaiser; Martin Montiel-Ruiz; Marcel Meury; Nadine Czudnochowski; Roberto Spreafico; Josh Dillen; Cindy Ng; Nicole Sprugasci; Katja Culap; Fabio Benigni; Rana Abdelnabi; Shi-Yan Caroline Foo; Michael A Schmid; Elisabetta Cameroni; Agostino Riva; Arianna Gabrieli; Massimo Galli; Matteo S Pizzuto; Johan Neyts; Michael S Diamond; Herbert W Virgin; Gyorgy Snell; Davide Corti; Katja Fink; David Veesler
Journal:  Science       Date:  2020-09-24       Impact factor: 47.728

View more
  85 in total

Review 1.  The humoral response and antibodies against SARS-CoV-2 infection.

Authors:  Hai Qi; Linqi Zhang; Bo Liu; Xinquan Wang
Journal:  Nat Immunol       Date:  2022-06-27       Impact factor: 31.250

2.  Imprinted antibody responses against SARS-CoV-2 Omicron sublineages.

Authors:  Young-Jun Park; Dora Pinto; Alexandra C Walls; Zhuoming Liu; Anna De Marco; Fabio Benigni; Fabrizia Zatta; Chiara Silacci-Fregni; Jessica Bassi; Kaitlin R Sprouse; Amin Addetia; John E Bowen; Cameron Stewart; Martina Giurdanella; Christian Saliba; Barbara Guarino; Michael A Schmid; Nicholas Franko; Jennifer Logue; Ha V Dang; Kevin Hauser; Julia di Iulio; William Rivera; Gretja Schnell; Florian A Lempp; Javier Janer; Rana Abdelnabi; Piet Maes; Paolo Ferrari; Alessandro Ceschi; Olivier Giannini; Guilherme Dias de Melo; Lauriane Kergoat; Hervé Bourhy; Johan Neyts; Leah Soriaga; Lisa A Purcell; Gyorgy Snell; Sean P J Whelan; Antonio Lanzavecchia; Herbert W Virgin; Luca Piccoli; Helen Chu; Matteo Samuele Pizzuto; Davide Corti; David Veesler
Journal:  bioRxiv       Date:  2022-06-02

3.  Potent monoclonal antibody-mediated neutralization of a divergent Hendra virus variant.

Authors:  Zhaoqian Wang; Ha V Dang; Moushimi Amaya; Yan Xu; Randy Yin; Lianying Yan; Andrew C Hickey; Edward J Annand; Bethany A Horsburgh; Peter A Reid; Ina Smith; John-Sebastian Eden; Kai Xu; Christopher C Broder; David Veesler
Journal:  Proc Natl Acad Sci U S A       Date:  2022-05-26       Impact factor: 12.779

Review 4.  Therapeutic Targeting of Innate Immune Receptors Against SARS-CoV-2 Infection.

Authors:  Mariya Farooq; Abdul Waheed Khan; Bilal Ahmad; Moon Suk Kim; Sangdun Choi
Journal:  Front Pharmacol       Date:  2022-06-30       Impact factor: 5.988

Review 5.  Immune response in COVID-19: what is next?

Authors:  Qing Li; Ying Wang; Qiang Sun; Jasmin Knopf; Martin Herrmann; Liangyu Lin; Jingting Jiang; Changshun Shao; Peishan Li; Xiaozhou He; Fei Hua; Zubiao Niu; Chaobing Ma; Yichao Zhu; Giuseppe Ippolito; Mauro Piacentini; Jerome Estaquier; Sonia Melino; Felix Daniel Weiss; Emanuele Andreano; Eicke Latz; Joachim L Schultze; Rino Rappuoli; Alberto Mantovani; Tak Wah Mak; Gerry Melino; Yufang Shi
Journal:  Cell Death Differ       Date:  2022-05-17       Impact factor: 12.067

Review 6.  Antibody-mediated neutralization of SARS-CoV-2.

Authors:  Henning Gruell; Kanika Vanshylla; Timm Weber; Christopher O Barnes; Christoph Kreer; Florian Klein
Journal:  Immunity       Date:  2022-05-13       Impact factor: 43.474

7.  Resilience of S309 and AZD7442 monoclonal antibody treatments against infection by SARS-CoV-2 Omicron lineage strains.

Authors:  James Brett Case; Samantha Mackin; John M Errico; Zhenlu Chong; Emily A Madden; Bradley Whitener; Barbara Guarino; Michael A Schmid; Kim Rosenthal; Kuishu Ren; Ha V Dang; Gyorgy Snell; Ana Jung; Lindsay Droit; Scott A Handley; Peter J Halfmann; Yoshihiro Kawaoka; James E Crowe; Daved H Fremont; Herbert W Virgin; Yueh-Ming Loo; Mark T Esser; Lisa A Purcell; Davide Corti; Michael S Diamond
Journal:  Nat Commun       Date:  2022-07-02       Impact factor: 17.694

8.  CLEC5A and TLR2 are critical in SARS-CoV-2-induced NET formation and lung inflammation.

Authors:  Pei-Shan Sung; Shao-Ping Yang; Yu-Chun Peng; Cheng-Pu Sun; Mi-Hwa Tao; Shie-Liang Hsieh
Journal:  J Biomed Sci       Date:  2022-07-11       Impact factor: 12.771

9.  Assessing the Mobility of Severe Acute Respiratory Syndrome Coronavirus-2 Spike Protein Glycans by Structural and Computational Methods.

Authors:  Soledad Stagnoli; Francesca Peccati; Sean R Connell; Ane Martinez-Castillo; Diego Charro; Oscar Millet; Chiara Bruzzone; Asis Palazon; Ana Ardá; Jesús Jiménez-Barbero; June Ereño-Orbea; Nicola G A Abrescia; Gonzalo Jiménez-Osés
Journal:  Front Microbiol       Date:  2022-04-15       Impact factor: 5.640

Review 10.  Innate immunity: the first line of defense against SARS-CoV-2.

Authors:  Michael S Diamond; Thirumala-Devi Kanneganti
Journal:  Nat Immunol       Date:  2022-02-01       Impact factor: 31.250

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.